Hong Kong Office REITs Stock News

Earlier in December, Giant Biogene Holding announced a share repurchase plan, following recent analyst coverage from Citic Securities, Citi and UBS. The buyback move is being read as a signal of management confidence and a direct attempt to enhance shareholder value. With the share repurchase plan now in place, we’ll explore how this capital allocation decision shapes Giant Biogene’s broader investment narrative. AI is about to change healthcare. These 30 stocks are working on everything...

Key Insights Hysan Development's significant private companies ownership suggests that the key decisions are influenced...

It's not a stretch to say that Luk Fook Holdings (International) Limited's ( HKG:590 ) price-to-earnings (or "P/E...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

ASMPT Limited ( HKG:522 ), is not the largest company out there, but it received a lot of attention from a substantial...

Sunlight (1977) Holdings Limited ( HKG:8451 ) shareholders have had their patience rewarded with a 42% share price jump...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

The Shandong Molong Petroleum Machinery Company Limited ( HKG:568 ) share price has fared very poorly over the last...

Viewing insider transactions for Longfor Group Holdings Limited's ( HKG:960 ) over the last year, we see that insiders...

The China Tianrui Automotive Interiors Co., LTD ( HKG:6162 ) share price has softened a substantial 27% over the...

Kinetic Development Group Limited ( HKG:1277 ) shares have retraced a considerable 25% in the last month, reversing a...

Wondering if Meituan is finally a bargain after years of volatility, or just another value trap in Chinese tech? This breakdown is designed to help you decide with a clear, valuation-led lens. The stock has inched up 2.2% over the last week even as it remains down 33.9% year to date and 37.3% over the past year, a combination that often signals shifting views on risk and long-term upside. Much of the recent movement has been shaped by ongoing headlines about China’s consumer recovery,...

The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Wynn Macau fair value estimate is HK$10.77 Current share price...

Wanguo Gold Group recently reported past results showing a 42.6% increase in revenue and a Return on Equity of 27.77%, accompanied by technical indicators pointing to oversold conditions and potential for a rebound. The combination of strong profitability metrics and signals of an oversold bounce is drawing fresh attention to how Wanguo’s diversified mining operations fit within the basic materials sector. Next, we will examine how Wanguo’s strong Return on Equity reshapes its investment...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...

Tang Palace (China) Holdings Limited's ( HKG:1181 ) price-to-sales (or "P/S") ratio of 0.2x may look like a pretty...

With a price-to-earnings (or "P/E") ratio of 7.6x C&D International Investment Group Limited ( HKG:1908 ) may be...

Key Insights Insiders appear to have a vested interest in Beijing Chunlizhengda Medical Instruments' growth, as seen by...

Key Insights MGM China Holdings' significant public companies ownership suggests that the key decisions are influenced...

3SBio Inc. recently completed a follow-on equity offering of HK$3.12 billion via a subsequent direct listing, issuing 105,169,500 ordinary shares at HK$29.62 each. The fundraise, paired with the planned divestment of its cash-generating hair-loss unit, underlines 3SBio’s push to become a focused innovator in late-stage biopharmaceuticals. With the shares posting a 10.14% seven-day decline, we’ll explore how this capital raise and portfolio refocus reshape 3SBio’s investment narrative. Find...

China Petroleum & Chemical (SEHK:386) is back in focus as China’s natural gas demand is projected to grow 5% next year, while Sinopec scales up carbon capture projects and explores new CCUS partnerships. See our latest analysis for China Petroleum & Chemical. Those CCUS moves and the improving gas demand backdrop seem to be nudging sentiment in Sinopec’s favor, with the share price at HK$4.42 and a 90 day share price return of 4.74%. The five year total shareholder return of 102.74% suggests...